Sunday, June 14, 2026

SC-Paragon Rubber Industries Vs. Pragati Rubber Mills

Composite Suits Under Copyright and Trade Mark Laws: When Jurisdiction Cannot Be Manufactured by Joinder

An Analysis of Paragon Rubber Industries v. Pragati Rubber Mills and Ors. (2013)

Introduction

In the arena of intellectual property litigation in India, one of the most practically important yet frequently misunderstood questions concerns the territorial jurisdiction of courts. Where can a plaintiff file a suit? Can a plaintiff combine two different legal claims — one under copyright law and one under trade mark law — in a single suit filed in a court that has jurisdiction over only one of those claims? The Supreme Court of India, in its landmark judgment in Paragon Rubber Industries v. Pragati Rubber Mills and Ors., decided on 29th November 2013, answered these questions with admirable clarity and finality.

The case arose from a long-running dispute between two footwear manufacturers, one based in Kerala and the other in Punjab, over the alleged infringement of trademark and copyright. The plaintiff chose to file a combined suit in the District Court at Kottayam, Kerala, relying on the special jurisdictional provision under Section 62(2) of the Copyright Act, 1957, which allows a plaintiff to sue in the court where he or she resides or carries on business — even if the defendant has no connection to that place. The central controversy was whether this provision could also pull along a separate cause of action under trade mark law, thereby conferring jurisdiction on the Kottayam court over a claim it would not otherwise be competent to try.

The Supreme Court, in a bench comprising Justice S.S. Nijjar and Justice A.K. Sikri, dismissed both the appeals arising from cross-petitions and upheld the High Court of Kerala's finding that such a composite suit was not maintainable. The decision has significant implications for intellectual property practitioners and litigants across India, and it settles a question that had seen some degree of judicial uncertainty in earlier decisions.

Factual and Procedural Background

The plaintiff in this case, Paragon Rubber Industries, is a company engaged in the manufacturing and marketing of footwear and is located in the state of Kerala. The company had been in this business since 1975, operating under a registered trademark and also holding a registered copyright associated with that trademark and its artistic representation. The defendant, Pragati Rubber Mills and others, is similarly a footwear manufacturer and marketer, but is based in Jalandhar, Punjab. The defendant also claimed to operate under a registered trademark and copyright bearing the name PRAGATI or PARAGATI, along with a distinctive device featuring a lion.

The seeds of the dispute were sown when the plaintiff alleged that the defendant's use of a similar trademark and artistic label amounted to infringement of both its copyright and its trade mark. On 19th March 2001, the plaintiff instituted a suit, registered as O.S. No. 2 of 2001, before the District Courts at Kottayam in Kerala. The suit sought relief under two separate statutes simultaneously — the Copyright Act, 1957 (referred to in the judgment as the '1957 Act') and the Trade and Merchandise Marks Act, 1958 (referred to as the '1958 Act'). Crucially, the plaintiff's own plaint admitted that the defendant's goods were not sold in Kottayam and that the defendant did not reside or carry on business within the territorial jurisdiction of the Kottayam court. The plaintiff's sole basis for filing the suit in Kottayam was Section 62(2) of the 1957 Act, which permits the plaintiff to file a copyright suit in the court within whose jurisdiction the plaintiff resides or carries on business.

The defendant responded by filing an application under Order VII Rule 11 of the Code of Civil Procedure, 1908, being I.A. No. 322 of 2004, seeking rejection of the plaint on the ground that the Kottayam court lacked territorial jurisdiction to try the suit. The trial court dismissed this application on 22nd March 2004, directing that the issue of jurisdiction would be decided at the final stage of the suit, that is, after full trial. Dissatisfied with this deferral, the defendant took the matter to the High Court of Kerala at Ernakulam by filing a Civil Revision Petition, being CRP No. 363 of 2004. The High Court, by order dated 16th June 2004, allowed the revision and directed the trial court to determine the issue of territorial jurisdiction afresh and treat it as a preliminary issue, meaning it should be decided at the outset before the main trial proceeds.

Consequently, the trial court examined jurisdiction as a preliminary issue and passed an order on 6th October 2004 holding that it did have jurisdiction to entertain the suit, relying primarily on Section 62(2) of the 1957 Act. The defendant challenged this order once again before the High Court, filing C.R.P. No. 1417 of 2004. After a detailed consideration of the matter, the High Court, by its impugned judgment dated 15th March 2011, held that the trial court's finding was incorrect. The High Court set aside the trial court's order but, in a significant exercise of discretion, granted the plaintiff the liberty to amend the plaint so as to restrict the suit to a form that would be maintainable before the Kottayam court. Both parties were aggrieved by this outcome and filed Special Leave Petitions before the Supreme Court, which were admitted and converted into Civil Appeal No. 10745 of 2013 and Civil Appeal No. 10746 of 2013 respectively.

The Core Dispute

The legal controversy at the heart of this case revolved around one fundamental question: when a plaintiff files a single suit combining claims under the Copyright Act, 1957 and the Trade and Merchandise Marks Act, 1958, and files that suit in a court that has jurisdiction to try only the copyright claim (by virtue of Section 62(2) of the 1957 Act) but not the trade mark claim, is such a composite suit maintainable?

The plaintiff, through its counsel Mr. Siddhartha Dave, argued vigorously that the suit was perfectly maintainable. The primary contention was that Section 62(2) of the 1957 Act was a special provision designed by Parliament specifically to enable copyright holders who might be resident in one part of the country to sue for infringement in a court closer to their home, rather than being forced to travel to wherever the defendant resides or does business. The provision, it was argued, conferred an additional forum — a court option over and above the normal ones prescribed by Section 20 of the Code of Civil Procedure. The plaintiff further argued that the trade mark claim in the suit was merely incidental to the copyright claim — it was not a standalone, independent cause of action but was subordinate and ancillary to the copyright grievance. When the trade mark relief is incidental in nature, the composite suit ought to be maintainable, because the court's jurisdiction under the copyright provision would naturally extend to grant incidental relief.

The plaintiff also drew attention to the fact that the Trade Marks Act, 1999 — the successor legislation to the 1958 Act — had itself incorporated a provision similar to Section 62(2) of the Copyright Act in its Section 134(2). Under this newer provision, a trade mark suit could also be filed where the plaintiff resides. The plaintiff argued that since the 1999 Act was applicable by the time the matter was being adjudicated, the Kottayam court should be allowed to exercise jurisdiction under the 1999 Act's provisions as well, making the continuation of the proceedings in Kottayam legally tenable.

Additionally, the plaintiff submitted that there existed an apparent conflict between three Supreme Court decisions — Exphar SA v. Eupharma Laboratories Ltd. (2004) 3 SCC 688, Dhodha House v. S.K. Maingi (2006) 9 SCC 41, and Dabur India Ltd. v. K.R. Industries (2008) 10 SCC 595 — and that the matter ought to be referred to a larger bench for authoritative resolution.

The defendant's position was straightforward: the suit, as framed, was a composite suit combining two independent causes of action under two different statutes. The court at Kottayam had jurisdiction under the copyright statute alone. Jurisdiction over the trade mark claim could not be conferred on the Kottayam court simply because the two claims happened to be joined in a single plaint. The defendant further pointed out that the 1999 Trade Marks Act, which the plaintiff sought to invoke, came into force only on 15th September 2003, whereas the suit was filed on 19th March 2001. The law applicable to the suit was therefore the 1958 Act, which did not contain any provision for additional forum selection akin to Section 62(2) of the 1957 Act.

Reasoning and Analysis of the Court

The Supreme Court approached the case with the clarity of a court that had already considered substantially similar questions in previous decisions. At the very outset, the bench observed that the issues raised were no longer res integra — meaning they were not fresh, open questions but had already been decided — and that the answers were to be found in the ratio of the judgments in Dhodha House (supra) and Dabur India (supra).

The Dhodha House Decision

The Supreme Court began its analysis by referring to the Dhodha House case [Dhodha House v. S.K. Maingi, MANU/SC/2524/2005 : (2006) 9 SCC 41], where the precise question — whether a court could exercise jurisdiction over a composite suit involving both copyright and trade mark claims solely on the basis of Section 62(2) of the 1957 Act — had been directly addressed. The court in Dhodha House had formulated the question clearly: whether causes of action arising under both the 1957 Act and the 1958 Act, even if overlapping, would allow a suit to be maintained in a court that has jurisdiction only by virtue of Section 62(2) of the 1957 Act?

The answer given by the Supreme Court in Dhodha House was clear: Section 62(2) of the 1957 Act was an additional forum — a parliamentary concession to copyright holders who might not otherwise be able to sue conveniently. Parliament was well aware of this provision when it enacted the Trade and Merchandise Marks Act in 1958, and yet deliberately chose not to include a similar additional forum provision in that Act. This deliberate omission, the court held, must be treated as a conscious legislative decision. It is a well-settled principle that courts should not readily presume the existence of a jurisdiction that has not been expressly conferred by statute.

Further, Dhodha House established a critical principle regarding composite suits and the Code of Civil Procedure: merely joining two causes of action in a single suit cannot create or confer jurisdiction on a court that would otherwise lack it with respect to one of those causes of action. A court must have jurisdiction over all the causes of action joined in a suit. If it has jurisdiction over one but not the other, the composite suit as a whole is not maintainable. The recourse to an additional forum is permissible only when both causes of action arise within the jurisdiction of the court that has the competence to decide all the issues.

The Dabur India Decision

The court then turned to Dabur India Ltd. v. K.R. Industries [MANU/SC/2244/2008 : (2008) 10 SCC 595], which had revisited and elaborated upon the Dhodha House principles. In Dabur India, the Supreme Court had explained what exactly is meant by a 'composite suit' in this context. A composite suit, the court clarified, is not simply any suit where two different statutory claims are clubbed together. Rather, a true composite suit within the meaning of the copyright jurisprudence is one that is fundamentally based on a copyright infringement claim, and where the court's powers are additionally invoked with respect to some incidental relief — relief that the court is otherwise competent to grant. In such a situation, the suit does not lose its character as a copyright suit merely because incidental relief is also sought.

However — and this was the critical distinction — Dabur India also made clear that two entirely separate causes of action, each founded on different facts and different statutory rights and liabilities, cannot be clubbed together under the guise of a 'composite suit' to manufacture jurisdiction in a court that lacks competence over one of them. Order 2 Rule 3 of the Code of Civil Procedure, which deals with joinder of causes of action, cannot be used as a device to create territorial jurisdiction where none exists.

No Conflict Between Dhodha House, Dabur India, and Exphar SA

The plaintiff had argued that there was a conflict between these decisions and that the matter should be referred to a larger bench. The Supreme Court firmly rejected this contention. Both Dhodha House and Dabur India, read together, consistently hold the same principle — that jurisdiction cannot be manufactured by joining two causes of action in a single suit. The Dabur India decision was not contradicting Dhodha House but rather explaining and refining it.

As for the Exphar SA case [Exphar SA v. Eupharma Laboratories Ltd., MANU/SC/0148/2004 : (2004) 3 SCC 688], the Supreme Court noted that Dabur India had already distinguished it. Exphar SA had dealt with a narrower and different question — specifically, whether Section 62(2) of the 1957 Act was to be read restrictively in a manner that would deprive copyright holders of its benefit merely because they had been served with cease-and-desist notices. The court in Exphar SA had rightly held that Section 62(2) should be construed broadly to facilitate copyright holders, and that the provision prescribed an additional ground for jurisdiction over and above Section 20 of the Code. However, this principle of liberal construction of Section 62(2) within its own domain did not extend to using Section 62(2) as a vehicle to drag in a completely different cause of action under a different statute. Dabur India had explained this distinction with precision, and the Supreme Court in the present case agreed that there was no real conflict warranting a reference to a larger bench.

Applying the Law to the Facts

Applying these principles to the facts of the present case, the Supreme Court found the matter straightforward. The plaintiff's own plaint had candidly admitted that the defendant's goods were not available in Kottayam and that the defendant did not reside or carry on business within the territorial jurisdiction of the Kottayam court. The only basis for filing the suit in Kottayam was Section 62(2) of the 1957 Act. The plaintiff had then attempted, in the words of the court, to 'camouflage' the lack of jurisdiction under the 1958 Act by confusing, mixing up, and intermingling the two causes of action in a single plaint.

The court was unequivocal: the plaintiff was fully aware that the Kottayam court had no jurisdiction to try the trade mark claim under the 1958 Act. Joining the trade mark claim with the copyright claim could not cure this deficiency. The composite suit, as framed, was not maintainable.

On the Trade Marks Act, 1999

The court also dealt decisively with the plaintiff's argument based on Section 134 of the Trade Marks Act, 1999. The 1999 Act does contain, in Section 134(2), a provision analogous to Section 62(2) of the 1957 Act — allowing a trade mark suit to be filed where the plaintiff resides. However, the 1999 Act, though enacted on 30th December 1999, was brought into force only on 15th September 2003 by a notification published in the Gazette of India. The present suit had been filed on 19th March 2001 — before the 1999 Act came into force. Section 159(4) of the 1999 Act itself makes clear that suits initiated under the 1958 Act would continue to be governed by that Act. Therefore, the applicable law for adjudicating the trade mark aspects of the suit remained the 1958 Act, which did not grant any additional forum. The High Court had correctly concluded that Section 134 of the 1999 Act could not assist the plaintiff in this case.

The Question of Allowing Plaint Amendment

Having concluded that the composite suit was not maintainable, the Supreme Court then addressed the separate controversy raised by the defendant in the second appeal. The defendant had challenged the High Court's order granting the plaintiff liberty to amend the plaint, arguing that once the suit was found to be non-maintainable, the court should have simply rejected it outright.

The Supreme Court declined to interfere with the High Court's exercise of discretion on this point. The reasoning was pragmatic and thoughtful: the High Court was conscious of the fact that under the 1999 Act (which came into force in 2003 and introduced Section 134(2)), a composite suit would indeed be maintainable in the Kottayam court. The High Court chose to grant the plaintiff an opportunity to amend the plaint — presumably to reformulate the suit so as to confine it to the copyright claim, over which the Kottayam court undeniably had jurisdiction, and to deal with the trade mark claim separately or allow it to be pursued under the now-applicable 1999 Act framework. This was a discretionary decision aimed at avoiding multiplicity of proceedings, and the Supreme Court found no error, perversity, or illegality in its exercise. The defendant could not dispute that for a pure copyright suit, the Kottayam court had full and undeniable jurisdiction under Section 62(2) of the 1957 Act. The order permitting amendment was therefore sustained.

Final Decision of the Court

The Supreme Court dismissed both Civil Appeal No. 10745 of 2013 (filed by the plaintiff Paragon Rubber Industries) and Civil Appeal No. 10746 of 2013 (filed by the defendant Pragati Rubber Mills) with no order as to costs. The judgment of the High Court of Kerala dated 15th March 2011 in CRP No. 1417 of 2004 was upheld in its entirety. The composite suit, as originally filed, was held not maintainable before the District Court at Kottayam. However, the liberty granted by the High Court to the plaintiff to amend the plaint was also confirmed, giving the plaintiff an opportunity to restructure its claims so as to make the suit maintainable.

Point of Law Settled

The case settles several important points of law in the domain of intellectual property litigation in India. First, Section 62(2) of the Copyright Act, 1957 grants an additional forum to a copyright owner — the court where the plaintiff resides or carries on business — but this additional forum is available only for copyright claims and cannot automatically extend to trade mark claims under the Trade and Merchandise Marks Act, 1958 or any other separate statute. Second, a composite suit combining copyright and trade mark claims is not maintainable in a court that has jurisdiction over only the copyright claim. Jurisdiction over all causes of action joined in a suit must exist independently; it cannot be conjured by merely clubbing two causes of action together in a single plaint. Third, the Trade Marks Act, 1958 did not contain any additional forum provision equivalent to Section 62(2) of the 1957 Act, and this omission was a deliberate legislative choice. Courts cannot read such a provision into the 1958 Act by implication or analogy. Fourth, the Trade Marks Act, 1999, while containing Section 134(2) which provides an additional forum for trade mark suits similar to the copyright provision, would apply only to suits filed after 15th September 2003 — the date on which the 1999 Act came into force. Suits filed before that date under the 1958 Act remain governed by the 1958 Act by virtue of Section 159(4) of the 1999 Act. Fifth, a composite suit within the framework of copyright law refers to a suit principally founded on copyright infringement where incidental relief is additionally claimed — not a suit combining two entirely different causes of action under two different statutes, each with its own independent factual foundation.

 

Case Details

Title: Paragon Rubber Industries Vs. Pragati Rubber Mills and Ors. AND Pragathi Rubber Mills and Ors. v. Paragon Rubber Industries

Date of Order: 29th November 2013

Case Number: Civil Appeal No. 10745 of 2013 (Arising out of SLP (C) No. 22280 of 2011) and Civil Appeal No. 10746 of 2013 (Arising out of SLP (C) No. 33453 of 2011)

Neutral Citation: MANU/SC/1247/2013

Court: Supreme Court of India

Hon'ble Judges: Justice S.S. Nijjar and Justice A.K. Sikri

 

Disclaimer: Readers are advised not to treat this as substitute for legal advise as it may contain errors in perception, interpretation, and presentation

Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi

 

Suggested SEO Titles for Legal Journal

1. Composite Suits Under Copyright and Trade Mark Law in India: Can Section 62(2) Confer Jurisdiction Over Trade Mark Claims?

2. Paragon Rubber Industries v. Pragati Rubber Mills: Supreme Court Settles Territorial Jurisdiction in IP Composite Suits

3. Section 62(2) Copyright Act 1957 and Jurisdiction in Composite Suits: A Supreme Court Analysis

4. When Does Joinder of Causes of Action Confer Jurisdiction? Lessons from Paragon Rubber Industries Case

5. Trade Mark and Copyright Composite Suits in India: Limits of Section 62(2) of the Copyright Act

6. Territorial Jurisdiction in Intellectual Property Suits: Composite Suit Doctrine Explained

7. Dhodha House, Dabur India, and Paragon Rubber: Resolving the Composite Suit Jurisdiction Debate

 

SEO Tags

Composite suit, territorial jurisdiction, Copyright Act 1957, Section 62(2), Trade Marks Act 1999, Trade and Merchandise Marks Act 1958, Section 134, Paragon Rubber Industries, Pragati Rubber Mills, Supreme Court of India, intellectual property, copyright infringement, trademark infringement, Dhodha House case, Dabur India case, Exphar SA case, Order 2 Rule 3 CPC, res integra, additional forum, joinder of causes of action, District Court Kottayam, Kerala High Court, IP litigation India, jurisdiction in copyright suits, jurisdiction in trademark suits, IP law India, footwear trademark dispute, AdvocateAjayAmitabhSuman, IPAdjutor

 

Headnote

Held — A composite suit combining claims under the Copyright Act, 1957 and the Trade and Merchandise Marks Act, 1958 is not maintainable in a court that has territorial jurisdiction only by virtue of Section 62(2) of the Copyright Act. Jurisdiction cannot be conferred upon a court merely by joining two independent causes of action in a single suit when the court lacks jurisdiction over one of them. Parliament's deliberate omission of an additional forum provision from the 1958 Act must be respected and cannot be supplied by implication. The Trade Marks Act, 1999, though containing Section 134(2) analogous to Section 62(2) of the Copyright Act, applies only to suits filed after 15th September 2003, when the 1999 Act came into force; suits filed before that date under the 1958 Act remain governed by the 1958 Act by virtue of Section 159(4) of the 1999 Act. The High Court's discretionary order permitting the plaintiff to amend the plaint to make the suit maintainable over the copyright claim alone was upheld as a proper exercise of discretion aimed at avoiding multiplicity of proceedings. Both appeals dismissed. No conflict found between Dhodha House v. S.K. Maingi [(2006) 9 SCC 41], Dabur India Ltd. v. K.R. Industries [(2008) 10 SCC 595], and Exphar SA v. Eupharma Laboratories Ltd. [(2004) 3 SCC 688].

SC-Novartis AG Vs. Union of India

Novartis AG v. Union of India: India's Landmark Stand Against Evergreening of Pharmaceutical Patents

 

Introduction

Few judgments in the history of intellectual property law in India have attracted as much national and international attention as the Supreme Court of India's decision in Novartis AG v. Union of India and Others, reported as (2013) 6 SCC 1, decided on April 1, 2013. This case raised a question that sat at the very crossroads of patent law, public health, access to medicines, and the obligations of a developing nation under international trade agreements. At its heart, the case asked a simple but deeply consequential question: should India grant a patent to a new crystalline form of an already known anti-cancer drug merely because the new form had improved physical properties, even when those improved properties did not translate into a meaningfully better therapeutic outcome for patients?

The drug in question was Gleevec or Glivec, sold by Novartis AG, a Swiss pharmaceutical giant, and used for the treatment of a deadly blood cancer called chronic myeloid leukaemia (CML) as well as certain other tumour-related conditions. The active pharmaceutical ingredient in Gleevec was the beta-crystalline form of Imatinib Mesylate, a compound derived from a broader family of chemical substances. Novartis had been selling Gleevec in India under a price that placed it out of reach for millions of patients. Generic manufacturers, particularly Indian pharmaceutical companies, were producing significantly cheaper versions of the same drug, which allowed patients across India and other developing nations to access life-saving treatment. The patent battle was thus not merely a corporate dispute. It was a contest between the patent rights of a multinational company and the right to life of thousands of cancer patients who depended on affordable medicines.

The case not only tested the limits of India's patent law, particularly the unique provision in Section 3(d) of the Patents Act, 1970 as amended by the Patents (Amendment) Act, 2005, but also examined whether India's approach to pharmaceutical patenting was consistent with its obligations under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) under the World Trade Organization. The Supreme Court, in its unanimous judgment delivered by a Bench of Justices Aftab Alam and Ranjana P. Desai, dismissed Novartis's appeals and refused the patent. The decision sent a clear message to the world: India's patent law, particularly Section 3(d), was not a mere procedural hurdle but a substantive requirement designed to prevent the practice of "evergreening," which is the attempt by pharmaceutical companies to extend their monopoly over a drug by obtaining patents on minor modifications of a known substance without any real therapeutic improvement.

 

Factual and Procedural Background

The origin of this dispute lies in an invention by Dr. Jürg Zimmermann, a scientist who worked for Ciba Geigy (which later merged with Sandoz in 1996 to form Novartis). Dr. Zimmermann invented a family of chemical compounds known as N-phenyl-2-pyrimidine-amine derivatives, which had the property of inhibiting certain tyrosine kinases — enzymes that play a role in the growth of cancer cells. This invention was patented in Europe and in the United States, where it became known as Zimmermann Patent No. 5,521,184, granted by the United States Patent and Trade Mark Office (USPTO) on May 28, 1996. The Zimmermann Patent covered the broad family of compounds, and within that family, the compound specifically identified as Example 21 — later given the international non-proprietary name "Imatinib" — was disclosed, along with its pharmaceutically acceptable salts, including Imatinib Mesylate (the methanesulfonic acid salt of Imatinib).

Novartis subsequently developed Imatinib Mesylate into a drug substance and eventually isolated a specific crystalline form of it — the beta-crystalline form — which it called beta-IM or β-IM. A subsequent US patent, Zimmermann Patent No. 6,894,051 B1, dated May 17, 2005, was granted to Novartis specifically for the beta-crystalline form (β-IM) of Imatinib Mesylate. Novartis marketed the drug under the brand name Gleevec in the United States and Glivec in other countries including India.

In India, Novartis filed a patent application in July 1998 for the beta-crystalline form of Imatinib Mesylate — that is, for β-IM — at the Chennai Patent Office. This application, numbered 1602/MAS/1998, claimed that the beta-crystalline form of Imatinib Mesylate was a new and patentable invention distinct from anything previously disclosed, including the Zimmermann Patent. The application was filed during the period when Indian patent law did not yet allow product patents for pharmaceutical substances, as Section 5 of the Patents Act, 1970 then prohibited product patents for drugs. In 1999, the Indian Government issued an Ordinance that created a "mailbox" mechanism under Article 70.8 of TRIPS, allowing applications for pharmaceutical product patents to be stored and examined once India's obligations to grant such patents under TRIPS kicked in, which happened when the Patents (Amendment) Act, 2005 came into force on January 1, 2005. Novartis's application thus remained in the "mailbox" until the 2005 Amendment opened the door for its examination.

On January 25, 2006, the Assistant Controller of Patents and Designs, Chennai, rejected Novartis's patent application on two main grounds: first, that the compound Imatinib Mesylate was already known from the Zimmermann Patent and was therefore not novel or did not involve an inventive step; and second, that the subject compound, being merely a new form of a known substance with no significantly enhanced efficacy, was excluded from patentability by virtue of Section 3(d) of the amended Patents Act, 1970.

Aggrieved by this rejection, Novartis filed appeals before the Intellectual Property Appellate Board (IPAB), Madras. In the meantime, Novartis also filed a Writ Petition in the High Court of Madras challenging the constitutional validity of Section 3(d) of the Patents Act, arguing that this provision was inconsistent with India's obligations under the TRIPS Agreement and was also vague and arbitrary in violation of Article 14 of the Constitution of India. The High Court, on August 6, 2007, in its decision in Novartis AG v. Union of India, (2007) 4 MLJ 1153, rejected the challenge to Section 3(d)'s constitutionality and its compatibility with TRIPS, holding that Section 3(d) was not violative of any constitutional provision and that TRIPS itself gave member nations the flexibility to define the patentability standards as suited their national interests. The High Court did not, however, deal with the merits of the patent claim itself, leaving those issues for the IPAB.

The IPAB, in its order dated June 26, 2009, partly affirmed the Controller's rejection. The IPAB disagreed with the Controller on the ground of lack of novelty and held that Imatinib Mesylate was not anticipated by the prior art. However, the IPAB upheld the rejection on the ground of Section 3(d), finding that Novartis had failed to demonstrate that β-IM had any significantly enhanced therapeutic efficacy as compared to the known substance Imatinib Mesylate. Novartis and other parties, including Natco Pharma Limited and Cancer Patients Aid Association, all filed appeals before the Supreme Court of India, challenging various aspects of the IPAB's reasoning.

Before the Supreme Court, Civil Appeals Nos. 2706-716 of 2013 (by Novartis), Civil Appeal No. 2728 of 2013 (by Natco Pharma Limited), and Civil Appeals Nos. 2717-27 of 2013 (by Cancer Patients Aid Association) were all heard together. The case thus came to be decided by the Supreme Court with a Bench of Justices Aftab Alam and Ranjana P. Desai.

 

The Dispute

The central legal dispute before the Supreme Court involved the correct interpretation and application of Section 3(d) of the Patents Act, 1970 as amended in 2005, along with Sections 2(1)(j) and 2(1)(ja) defining "invention" and "inventive step" respectively. However, several other important sub-disputes arose in the course of argument.

The first and primary question was whether Imatinib Mesylate — the parent substance from which β-IM was derived — was itself a "new" product when it came into being, or whether it was already a known substance taught by the Zimmermann Patent. This was significant because if Imatinib Mesylate itself was not a "new" product, then the two-stage claim by Novartis — that they invented first Imatinib Mesylate and then β-IM — could not be sustained. Novartis argued before the Supreme Court that Imatinib Mesylate was covered by the Zimmermann Patent (i.e., within its claims) but was not specifically disclosed or taught as a preparation in that patent, and therefore the step of going from Imatinib (the free base) to Imatinib Mesylate involved an inventive step. The respondents, on the other hand, particularly Cipla Ltd. (appearing through Mr. Harish N. Salve, Senior Advocate) and the Union of India, contended that Imatinib Mesylate was fully part of the teaching of the Zimmermann Patent, which disclosed preparing "pharmaceutically acceptable salts" of the compound Imatinib, and that the mesylate salt was an obvious variant known to persons skilled in pharmaceutical chemistry.

The second important sub-dispute was whether the claim for β-IM as a distinct invention could survive the test of Section 3(d) of the 1970 Act. Section 3(d) provides that the "mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance" shall not be considered an invention. The Explanation to Section 3(d) clarifies that salts, esters, polymorphs, metabolites, pure form, particle size, isomers, mixtures of isomers, complexes, combinations, and other derivatives of known substances shall be considered to be the same substance, unless they differ significantly in properties with regard to efficacy. Novartis argued that β-IM had enhanced efficacy because it had 30% more bioavailability than Imatinib in free-base form, and had better physical properties such as better flow, greater thermodynamic stability, and lower hygroscopicity. The respondents argued that bioavailability improvements and physico-chemical properties were not the same as enhanced therapeutic efficacy as required by Section 3(d), and that Novartis had not produced any research data comparing the therapeutic effect of β-IM with that of Imatinib Mesylate in treating patients.

The third significant dispute related to whether Section 3(d) was an ex majore cautela (out of abundant caution) provision that should be read as subordinate to the general invention tests in Sections 2(1)(j) and 2(1)(ja), or whether it was a substantive, independent test that applied to pharmaceutical substances over and above the tests of novelty and inventive step. Novartis contended that Section 3(d) was merely a precautionary or advisory provision and that if β-IM satisfied the standard tests of novelty and inventive step, Section 3(d) could not stand in the way of granting a patent. The respondents and the courts below had held to the contrary, and this view was ultimately affirmed by the Supreme Court.

A further dispute concerned whether Novartis's own representations in other jurisdictions — particularly before the US Patent Office where it had taken the position that Imatinib Mesylate was taught by the Zimmermann Patent — could bind it before Indian proceedings. The respondents argued that Novartis was blowing hot and cold by claiming in India that Imatinib Mesylate was a new product distinct from Zimmermann while having maintained in the United States that it was fully covered by Zimmermann, and that the principle of estoppel or issue estoppel ought to prevent Novartis from contradicting its own earlier positions.

 

Reasoning and Analysis of the Judges

The Supreme Court delivered a detailed, extensively researched judgment spanning over 100 paragraphs of substantive analysis, touching upon the history of Indian patent law, the international law obligations under TRIPS, the purpose and meaning of Section 3(d), the concept of "invention" and "inventive step" under Indian law, and the factual questions concerning the substance β-IM and its characteristics.

The Court began by examining the legislative history of patent law in India, going back to the pre-independence period and the Patents and Designs Act, 1911. The Judges traced the development of Indian patent law through the Justice Rajagopala Ayyangar Report of 1959, which had strongly recommended that India should not grant product patents in the pharmaceutical sector, and which led to the enactment of the Patents Act, 1970. The Ayyangar Report had specifically noted that allowing product patents in chemicals and pharmaceuticals would lead to monopolies that would be detrimental to public health in a developing country. The Court noted that when Section 5 of the 1970 Act, which barred product patents in drugs and food, was deleted as part of India's TRIPS compliance through the Patents (Amendment) Act, 2005, it was not done in isolation. The deletion of Section 5 was accompanied by the insertion of Section 2(1)(j) and Section 2(1)(ja) — which redefined "invention" and "inventive step" — as well as the amendment to Section 3(d) and the addition of its Explanation, which set up a higher threshold for patentability specifically aimed at pharmaceutical and chemical substances.

The Court quoted from and heavily relied upon Monsanto Co. v. Coramandal Indag Products (P) Ltd., (1986) 1 SCC 642, where the Supreme Court had explained the basic quid pro quo of patent law: an inventor is given a limited monopoly in exchange for publicly disclosing the invention so that at the end of the patent term, the invention falls into the public domain and the public benefits from it. The Court emphasized that the coverage of a patent (what it claims) cannot be wider than its disclosure (what it teaches), and that Patent Law in India should not develop in a direction where the scope of a patent is determined not by the intrinsic worth of the invention but by the clever drafting of claims by skilled lawyers.

On the first major factual question — whether Imatinib Mesylate was a known substance — the Court examined the Zimmermann Patent No. 5,521,184 in considerable detail and concluded that Imatinib Mesylate was indeed a known substance disclosed within that patent. The patent not only taught the use of "pharmaceutically acceptable salts" of Imatinib but also stated the anti-tumoral properties of the compound and its methanesulfonate salt. The Court also noted two published scientific articles from reputed journals — one titled "Inhibition of the Abl Protein-Tyrosine Kinase In Vitro and In Vivo by a 2-Phenylaminopyrimidine Derivative," published in the Cancer Research Journal (Issue January–February 1996) by Dr. Zimmermann himself, and another titled "Effects of a Selective Inhibitor of the Abl Tyrosine Kinase on the Growth of Bcr-Abl Positive Cells" published in Nature Medicine (1996) — both of which specifically discussed the anti-tumoral properties of Imatinib and its mesylate salt. The Court observed that in the face of these materials, it was difficult to see how Imatinib Mesylate could be regarded as a new product.

On the question of whether Novartis was bound by its earlier representations, the Court examined the fact that when Novartis obtained US Patent No. 6,894,051 B1 for β-IM, the US Board of Patent Appeals had proceeded on the basis that Zimmermann Patent No. 5,521,184 had the teaching for making of Imatinib Mesylate from Imatinib. The Court held that Novartis, having benefited from this finding and used it in its own case in the United States, was bound by it and could not take a contrary position before Indian courts. Therefore, the development of Imatinib Mesylate from Imatinib did not qualify as an "invention" under Sections 2(1)(j) and 2(1)(ja) of the Patents Act, 1970.

Turning to the second major question — whether β-IM satisfied the test of Section 3(d) — the Court undertook a careful analysis of the meaning of the word "efficacy" as used in that provision. Novartis had argued that "efficacy" should be read broadly to include physico-chemical properties like better flow, thermodynamic stability, lower hygroscopicity, and increased bioavailability, all of which, it was said, made β-IM a better product. The Court rejected this argument with a clear and firm ruling. It held that the word "efficacy" in the context of Section 3(d), when applied to a medicine, must mean "therapeutic efficacy" — that is, the ability of the medicine to produce the desired therapeutic result in treating the disease for which it is prescribed. The Judges relied upon the New Oxford Dictionary of English (1998 edition), the IUPAC Glossary of Terms Used in Medicinal Chemistry (1998), and Goodman and Gilman's pharmacological treatise to establish that in the context of medicines, "efficacy" means therapeutic effectiveness. The Court further examined the Explanation to Section 3(d), which lists salts, polymorphs, and other derivatives as being regarded as the same substance "unless they differ significantly in properties with regard to efficacy," and held that this also pointed to therapeutic efficacy rather than general physicochemical properties.

The Court further reasoned that the legislature had consciously worded the Explanation to specify that properties "inherent" to a form — such as hygroscopicity to a polymorph or solubility to a salt — should not be taken as enhancements in efficacy unless they translate directly into therapeutic gains. Improved bioavailability, by itself, does not necessarily result in better therapeutic outcomes. Novartis had not presented any clinical data, research study, or empirical evidence showing that β-IM was more effective than Imatinib Mesylate in treating CML or any other condition. On the contrary, the drug Gleevec as marketed in India (as well as in the United States) was labelled on its packaging as containing "Imatinib Mesylate Tablets 100 mg" with each film-coated tablet containing "100 mg Imatinib (as Mesylate)." There was no reference at all to β-IM on the packaging. The Court drew the logical inference that if what was actually sold and effective was Imatinib Mesylate — not the β-IM crystalline form specifically — then the patent claim for β-IM was essentially an attempt to monopolise what was, in effect, Imatinib Mesylate, which would otherwise not be patentable. This, the Court noted, was a classic example of what the pharmaceutical industry calls "evergreening."

The Court's analysis on the TRIPS compatibility of Section 3(d) was also significant, though it was largely affirming the High Court's earlier ruling. The Judges held that TRIPS does not define what must constitute an "invention" for patentability; Article 27 of TRIPS requires member states to grant patents for inventions that are new, involve an inventive step, and are capable of industrial application, but it leaves countries free to define the standards for these requirements in their own law. Section 3(d) is India's way of defining that a mere new form of a known pharmaceutical substance, without enhanced therapeutic efficacy, does not qualify as an "invention" for Indian patent law purposes. The Court thus held that Section 3(d) does not violate TRIPS.

The Court also expressed serious concern about the broader implications for patent law development in India. In one of the most quoted paragraphs of the judgment (Paragraph 134), the Court stated that patent law in India should not develop in a manner where the scope of a patent is determined not on the intrinsic worth of the invention but by the artful drafting of claims by skilful lawyers, and where patents are traded as a commodity not for the production and marketing of the patented products but to search for someone who may be sued for infringement of the patent. This was a clear judicial articulation of the philosophy underpinning India's approach to pharmaceutical patents, and it set a strong policy marker for future cases.

The Court further discussed and considered the dichotomy between patent "coverage" and patent "disclosure," relying on several academic treatises including Terrell on the Law of Patents (16th Edition), Chisum on Patents, and academic papers from the Saint Louis University Law Journal. It held that the fundamental rule underlying the grant of patents — that the monopoly granted to the inventor is limited to what he has actually disclosed — means that a patent's coverage cannot exceed its disclosure. This has direct implications for Novartis's claim, since what was disclosed in the Zimmermann Patent (including Imatinib Mesylate) could not be the basis for a new patent merely because a specific crystalline form was now being singled out.

Several judicial decisions from foreign jurisdictions were considered during the course of arguments before the Court, including Plant Genetic Systems, N.V. v. DeKalb Genetics Corpn., 315 F 3d 1335 (Fed Cir 2003); Chiron Corpn. v. Genentech Inc., 363 F 3d 1247 (Fed Cir 2004); A.C. Edwards Ltd. v. Acme Signs & Displays Ltd., 1992 RPC 131; Astellas Pharma Inc. v. Comptroller General of Patents, 2009 EWHC 1916 (Pat); Hogan, In re, 559 F 2d 595 (CCPA 1977); and Glaverbel S.A. v. British Coal Corpn. (No. 2), 1993 RPC 90. These were considered primarily in the context of the relationship between patent coverage and disclosure, though the Court did not mechanically follow foreign precedents in arriving at its conclusion under Indian law.

 

Final Decision of the Court

The Supreme Court, by its unanimous judgment dated April 1, 2013, dismissed the Civil Appeals filed by Novartis AG with costs and held as follows:

The subject product, β-crystalline-Imatinib Mesylate (β-IM), failed both the test of invention as laid down in Sections 2(1)(j) and 2(1)(ja) of the Patents Act, 1970 and the test of enhanced efficacy or patentability under Section 3(d) read with its Explanation. Imatinib Mesylate was found to be a known substance disclosed in the Zimmermann Patent No. 5,521,184. The development of Imatinib Mesylate from Imatinib did not constitute a new invention. β-IM, being a polymorph (a specific crystalline form) of Imatinib Mesylate, was a "new form of a known substance" for the purposes of Section 3(d). Novartis had not demonstrated, through any empirical, clinical, or research data, that β-IM had any enhanced therapeutic efficacy compared to Imatinib Mesylate, the known substance. The improved physical properties of β-IM — such as better flow, thermodynamic stability, lower hygroscopicity, and 30% increased bioavailability — were not sufficient by themselves to constitute "enhanced efficacy" for the purposes of Section 3(d), since efficacy in the context of a medicine means therapeutic efficacy, which must be judged strictly and narrowly. The patent application for β-IM was therefore rightly rejected. The Court upheld R. 55 of Patent Rules, 2003 and held that no violation of Article 21 of the Constitution of India was made out. The appeals filed by Natco Pharma Limited and Cancer Patients Aid Association were allowed to the extent of affirming the rejection of Novartis's patent claim.

 

Point of Law Settled in the Case

This judgment settled several important points of law with lasting significance for Indian patent jurisprudence.

The Supreme Court authoritatively held that "invention" and "patentability" under the Patents Act, 1970 are two distinct and separate concepts. A product may qualify as an "invention" in a general sense and yet may not be patentable if it falls within one of the exclusions in Section 3 of the Act. Section 3(d) is not an ex majore cautela clause but a substantive provision that independently and mandatorily applies to all pharmaceutical and chemical substances of the nature described therein.

The Court settled that in the context of a new form of a known pharmaceutical or chemical substance, the applicant must cumulatively satisfy two tests: first, the invention test under Sections 2(1)(j) and 2(1)(ja), and second, the enhanced therapeutic efficacy test under Section 3(d) read with its Explanation. Both tests must be independently satisfied; clearing one does not exempt the applicant from the other.

The Court definitively interpreted "efficacy" in Section 3(d) as meaning "therapeutic efficacy" in the case of medicines and pharmaceuticals — that is, the ability of the medicine to produce the desired therapeutic effect in treating the disease for which it is prescribed. Physico-chemical properties such as improved flow, better stability, reduced hygroscopicity, or even increased bioavailability, by themselves, do not amount to "enhanced efficacy" unless they are specifically connected to and proven to result in better therapeutic outcomes, which must be established through research or empirical data.

The Court also settled the principle that patent coverage cannot exceed patent disclosure, and that a patent application that draws its very claims and averments from a prior patent (in this case the Zimmermann Patent) while simultaneously claiming to be independent of that prior patent will be critically scrutinized. A party is bound by the positions it has taken and benefited from in foreign proceedings involving the same subject matter.

The ruling firmly placed Section 3(d) as India's principal legislative safeguard against "evergreening" in the pharmaceutical industry — the practice of repeatedly patenting minor modifications of a known drug to extend patent-based monopolies and delay the availability of affordable generic medicines. This was characterized not merely as a matter of patent law but as a matter of public health policy.

 

Case Details

Title: Novartis AG Vs. Union of India and Others (with Natco Pharma Limited v. Union of India and Others, and Cancer Patients Aid Association v. Union of India and Others)

Date of Order: April 1, 2013

Case Numbers: Civil Appeals Nos. 2706-716 of 2013 (Novartis AG); Civil Appeal No. 2728 of 2013 (Natco Pharma Limited); Civil Appeals Nos. 2717-27 of 2013 (Cancer Patients Aid Association) — arising out of SLPs (C) Nos. 20539-49 of 2009, SLP (C) No. 32706 of 2009, and SLPs (C) Nos. 12984-94 of 2013

Neutral Citation / Published Citation: (2013) 6 SCC 1

Court: The Supreme Court of India

Bench: Hon'ble Mr. Justice Aftab Alam and Hon'ble Mrs. Justice Ranjana P. Desai, JJ.

 

Disclaimer: Readers are advised not to treat this as substitute for legal advice as it may contain errors in perception, interpretation, and presentation.

Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi

 

Suggested SEO Titles

1.    Novartis AG v. Union of India 2013: The Supreme Court Judgment That Changed Pharmaceutical Patent Law in India

2.    Section 3(d) Patents Act Explained: How India Defeated Novartis in the Gleevec Patent Case

3.    Evergreening of Pharmaceutical Patents in India: Lessons from Novartis v. Union of India (2013) 6 SCC 1

4.    Therapeutic Efficacy Test Under Section 3(d) of the Indian Patents Act: The Novartis Gleevec Ruling

5.    Beta-Crystalline Imatinib Mesylate Patent Refused: Supreme Court of India on New Forms of Known Substances

6.    TRIPS Compliance and Indian Patent Law: Analysis of the Novartis Glivec Case

7.    Anti-Evergreening Provision in Indian Patent Law: A Detailed Analysis of (2013) 6 SCC 1

 

SEO Tags

Novartis AG v Union of India, Section 3d Patents Act 1970, Gleevec patent India, Glivec patent case, Imatinib Mesylate patent, beta crystalline Imatinib Mesylate, pharmaceutical patent India, evergreening of patents, therapeutic efficacy test, Indian patent law, Patents Amendment Act 2005, TRIPS and Indian patent law, Supreme Court patent judgment 2013, patent and public health India, Aftab Alam judgment, Ranjana Desai Supreme Court, Zimmermann Patent, Natco Pharma, Cancer Patients Aid Association, new form of known substance, Section 2(1)(j) Patents Act, Section 2(1)(ja) Patents Act, inventive step India, patent eligibility pharmaceutical, product patent India, IPAB judgment patent, patent mailbox India, CML cancer drug patent, affordable medicines India, generic medicines patent, IP law India, intellectual property landmark judgment, patent evergreening prevention, bioavailability patent India, polymorph patent India, AdvocateAjayAmitabhSuman, IPAdjutor

 

Headnote

Novartis AG v. Union of India, (2013) 6 SCC 1 — Supreme Court of India — Bench: Aftab Alam and Ranjana P. Desai, JJ. — Decided on April 1, 2013

Held: Under the Patents Act, 1970 as amended by the Patents (Amendment) Act, 2005, "invention" and "patentability" are distinct concepts, and a substance must satisfy both the general invention test under Sections 2(1)(j) and 2(1)(ja) and the enhanced efficacy test under Section 3(d) in order to qualify for a patent in India. Section 3(d) is a substantive anti-evergreening provision and not a mere precautionary clause. In the case of pharmaceutical and chemical substances, "efficacy" within Section 3(d) means "therapeutic efficacy" — the ability of the medicine to produce the desired therapeutic result in treating the disease — and not merely improved physico-chemical properties. A new crystalline polymorph (beta-crystalline Imatinib Mesylate, β-IM) of a known pharmaceutical substance (Imatinib Mesylate) that does not demonstrate enhanced therapeutic efficacy over the known substance through research/empirical data is not patentable under Indian law. Imatinib Mesylate, being a known substance disclosed in Zimmermann Patent No. 5,521,184 (US), the claim for β-IM also failed the invention test. The drug Gleevec/Glivec (β-IM) marketed and sold as Imatinib Mesylate with no reference to the beta-crystalline form on its packaging indicated a deceptive patent claim. Appeals by Novartis dismissed with costs. Section 3(d) held to be TRIPS-compatible. Patent coverage cannot exceed patent disclosure. Indian Patent Law should not develop in a manner where patents are traded as commodities for litigation rather than for genuine invention and production.

 

SC-National Bell Co. and Gupta Industrial Corporation Vs. Metal Goods Mfg. Co. (P) Ltd

Can a Number Be a Trademark? The Supreme Court's Landmark Ruling on Numerals, Distinctiveness, and the Seven-Year Shield

Introduction

Among the many intriguing questions that trademark law throws up, few are as counterintuitive as this: can a plain number — say, "50" — be someone's exclusive trademark? Most people would instinctively say no. Numbers feel like they belong to everyone, like the letters of the alphabet or the days of the week. Yet Indian trademark law, as interpreted by the Supreme Court of India in its judgment dated March 18, 1970 in National Bell Co. and Gupta Industrial Corporation v. Metal Goods Mfg. Co. (P) Ltd. and Anr., firmly answered that question in the affirmative, at least in the circumstances of that case. The judgment is a foundational ruling in Indian intellectual property law on several counts: it clarified the legal meaning of "distinctiveness" as applied to numerals, it explained the difference between a mark that is simply not registerable and one that is positively prohibited from registration, it settled the interpretation of the powerful seven-year conclusiveness rule under Section 32 of the Trade and Merchandise Marks Act, 1958, and it laid down the principle that mere neglect to prosecute every infringer does not amount to abandonment of a trademark. Decided at a time when India's organized cycle bell industry was finding its feet, the case has enduring relevance for anyone who wishes to understand what makes a trademark valid, how long it can be challenged, and under what circumstances it can be cancelled.

Factual and Procedural Background

The story begins in the cycle spare parts industry of mid-twentieth century India. Metal Goods Mfg. Co. (P) Ltd., the Respondent in these appeals, was a company that manufactured cycle bells and marketed them under the brand name "Asia." On November 20, 1953, it obtained registration of two trademarks: Registered Trade Mark No. 161543, being the numeral "50," and Registered Trade Mark No. 161544, being the word "Fifty." These two marks were registered in respect of the cycle bells manufactured by the company. For several years before the dispute arose, the company's "Asia 50" and "Asia Fifty" bells were being sold in the market, and the company's own sales statements showed a remarkable growth in business: from a value of Rs. 19,644 in the financial year 1949-50, the sales of bells under these marks climbed to Rs. 14.83 lacs by 1961-62, an extraordinary rise in business over a little more than a decade.

The two Appellants before the Supreme Court were National Bell Co. and Gupta Industrial Corporation, both based in Kapurthala in Punjab. National Bell Co. claimed to have been manufacturing cycle bells with numerals "33," "50," "51," and "40" inscribed on them since 1957. Gupta Industrial Corporation claimed to have been doing so with numerals "20," "50," and "60" inscribed on its bells since as far back as 1947. Both companies used the numeral "50" on their cycle bells and called their products "National 50" and "Gupta 50" respectively. The Respondent company filed suits against both these companies in the District Court at Lucknow for infringement of its registered trademarks, namely the numeral "50" and the word "Fifty." These suits were filed in the year 1959.

When the infringement suits were filed, the two Appellant companies adopted the strategy commonly used in trademark litigation: rather than simply defending the suits on their merits, they went on the offensive by challenging the very validity of the Respondent's registered trademarks. On April 24, 1961, the District Court at Lucknow stayed the infringement suits and gave the Appellant companies time to file rectification applications before the High Court under Section 111 of the Trade and Merchandise Marks Act, 1958. The Appellant companies accordingly filed two applications before the High Court seeking rectification of the register — in essence, asking the court to cancel the Respondent's registered trademarks.

The grounds urged by the Appellant companies in the rectification applications were threefold. First, they argued that the numeral "50" and the word "Fifty" were common to the trade at the time of original registration in 1953 and were never distinctive of the Respondent's goods. Second, they contended that many other manufacturers and dealers in the market were using the numeral "50" and the word "Fifty" on cycle bells, so that whatever distinctiveness those marks might once have had was now lost. Third, they alleged that the Respondent had not obtained registration with any bona fide intention of using the marks and had in fact not used them in any genuine sense before the date of the applications. They further alleged that the Respondent had made a fraudulent declaration at the time of registration by claiming to be the originator or proprietor of the marks "50" and "Fifty."

Both sides led extensive evidence before the learned Single Judge of the High Court, including oral testimony and documentary evidence such as price lists obtained from dealers in cycle spare parts. The learned Single Judge, after examining the evidence, made the following key findings: cycle bells with the numeral "50" inscribed on them had been in the Indian market before the Respondent obtained registration in 1953, and had continued in the market until about 1958, though from old imported stock rather than fresh imports since import of foreign cycle bells had been prohibited around 1952. He found no evidence of any fraud by the Respondent in obtaining the original registration. He found that the Appellant companies had not even alleged, let alone proved, that companies like Lucas or any other foreign manufacturer had obtained trademark registration for the numeral "50" or the word "Fifty." He held that Clause (a) of Section 32 — which deals with fraudulent registration — did not apply, and Clause (b) of Section 32 — which deals with contravention of Section 11 — also did not apply. However, on the question of Clause (c) of Section 32, he held that numerals are prima facie not distinctive, that the numeral "50" was being commonly used by several manufacturers and dealers after the registration, and that the mark "50" was therefore not distinctive at the commencement of the proceedings. He accordingly cancelled Trade Mark No. 161543 (the numeral "50"). As regards Trade Mark No. 161544 (the word "Fifty"), he held that there was no evidence of use by other parties and that since seven years had elapsed since registration, the mark could not be challenged on distinctiveness grounds, so he refused to cancel it.

Both the Appellant companies and the Respondent company filed appeals against this order before a Division Bench of the Punjab High Court in Letters Patent Appeal Nos. 38-D, 42-D, 39-D, and 43-D of 1963. The Division Bench, by its common judgment dated February 25, 1965, reversed the Single Judge's order cancelling the numeral "50" and upheld the validity of both registrations. The Division Bench found that while the numeral "50" had been used by foreign companies like Lucas on bells sold in India, those companies had used it merely as a type mark to distinguish one variety of bell from another, and not as a trademark at all. Import of such bells had stopped around 1952, and whatever sales continued until 1958 were from remaining old stocks. The Division Bench also noted the strong and sustained commercial performance of the Respondent's marks, with sales rising year on year, and held that on the facts, both marks remained distinctive at the relevant date of proceedings. The Appellant companies then appealed to the Supreme Court under certificate.

The Dispute

The central dispute before the Supreme Court was whether the two registered trademarks of the Respondent — the numeral "50" and the word "Fifty" — should be cancelled. More specifically, the Appellant companies pressed three arguments. They argued that since seven years had elapsed from the date of registration in 1953 by the time the rectification proceedings were launched in 1961, registration could still be challenged if the marks fell within the exceptions carved out in Section 32 of the Act. They contended that the marks were registered in contravention of Section 11 of the Act, which prohibits certain marks from being registered, including marks that would otherwise be "disentitled to protection in a court." They also argued that the marks were not distinctive at the commencement of the proceedings, bringing the case within Clause (c) of Section 32. The Respondent countered that Section 32 created a near-absolute shield after seven years, that the marks did not fall within any of the exceptions in Section 32, and that its consistent enforcement activity and rising sales demonstrated that the marks remained distinctive.

The legal questions were thus: what is the legal character of the seven-year shield under Section 32, what kinds of objections can still be raised after seven years have passed, what is the true meaning of Section 11(e)'s prohibition on marks "disentitled to protection in a court," and when can a mark be said to have lost its distinctiveness at the commencement of proceedings?

Reasoning and Analysis of the Judge

Justice J.M. Shelat, writing for a Bench composed of himself and Justice C.A. Vaidialingam, approached the matter methodically, working through the relevant provisions of the Trade and Merchandise Marks Act, 1958, before applying them to the facts.

The Court began by laying down the foundational concepts. Under Section 2(j) of the Act, a "mark" includes a word, letter, numeral, or any combination thereof. A "trade mark" under Section 2(v) is a mark used or proposed to be used in relation to goods to indicate a connection in the course of trade between the goods and some person having the right to use the mark. Under Section 9 of the Act, a trade mark can be registered in Part A of the register only if it contains or consists of at least one of the essential particulars listed in that section, one of which is "any other distinctive mark." Section 9(3) defines "distinctive" for the purposes of the entire Act as meaning "adapted to distinguish goods with which the proprietor of the trade mark is or may be connected in the course of trade from goods with which no such connection subsists." In determining distinctiveness, one must consider both whether the mark is inherently distinctive and whether by reason of its use it has in fact become distinctive.

The Court then explained the significance of Section 31 and Section 32 of the Act. Section 31 provides that registration is prima facie evidence of the validity of the trademark. This means that in any infringement suit or rectification proceeding, the registered proprietor does not have to prove his title from scratch — the certificate of registration itself does the job, placing the burden on the challenger. Section 32 goes a step further: it provides that after seven years have elapsed from the date of original registration, the registration shall be taken to be conclusively valid in all legal proceedings, including rectification applications under Section 56. This conclusiveness is absolute except in three limited situations: the original registration was obtained by fraud (Clause a), the trademark was registered in contravention of Section 11 or offends against Section 11 as of the date of proceedings (Clause b), or the trademark was not distinctive of the goods of the registered proprietor at the commencement of the proceedings (Clause c).

In the present case, the registration had taken place on November 20, 1953, and the rectification applications were filed in 1961, more than seven years later. The Court confirmed that no objection that the marks were not registerable under Section 9 at the time of original registration could be entertained at this stage. This meant the Appellants could not argue that numerals are inherently not distinctive and that the Respondent had failed to prove distinctiveness before the Registrar in 1953. That ship had sailed.

On the question of fraud under Clause (a) of Section 32, the Court agreed with both courts below that this ground was entirely unsupported. The Appellant companies had not even properly pleaded fraud, let alone proved it. This ground was accordingly set aside.

The most intellectually intricate part of the judgment dealt with the distinction between Section 9 (which sets out the requisites for registration) and Section 11 (which prohibits certain marks from being registered). The Appellants argued that since numerals are prima facie not distinctive, the marks "50" and "Fifty" were registered in contravention of Section 11(e), which prohibits marks that "would otherwise be disentitled to protection in a court." If this argument succeeded, the seven-year shield of Section 32 would not save the marks, since Clause (b) of Section 32 expressly keeps the Section 11 exception alive even after seven years.

The Court firmly rejected this argument. It drew a crucial distinction between a mark that is "not entitled to protection" and a mark that is "disentitled to protection." The former merely means a mark that did not qualify for registration because it lacked distinctiveness or some other requisite under Section 9. The latter means a mark that has some inherent legal disqualification — such as being likely to deceive, being contrary to law, being obscene, or being contrary to public morality — which makes it positively unfit to be protected by a court. The word "disentitled" carries with it the idea of an active disqualification, not merely the absence of a qualification.

In support of this interpretation, the Court relied upon the English case of Imperial Tobacco Co. Ltd. v. De Pasquali & Co. (35 R.P.C. 185), decided by the Court of Appeal in England, which had construed the equivalent provisions of the Trade Marks Act, 1905 (Sections 11 and 41 of that Act, corresponding to Sections 11 and 32 of the Indian Act). In that case, Swinfen Eady, M.R. had observed that Section 11 was a prohibition section — it dealt with what marks shall not be lawful to register, not with what marks satisfy the qualifications for registration. The mere fact that a mark did not comply with the requisites of Section 9 did not bring it within Section 11. The expression "disentitled to protection" was not equivalent to "not entitled to protection." A mark was "disentitled to protection" only if there was some illegal or inherent disqualification in the mark itself — such as the likelihood of deception, obscenity, illegality, or something similarly substantive — not merely because it failed to satisfy the distinctiveness test of Section 9. The Supreme Court adopted this reasoning as the correct interpretation of the Indian provision as well.

The practical consequence of this ruling was significant: the Appellants could not bring the trade marks within the Clause (b) exception to Section 32 merely by arguing that numerals are not inherently distinctive. Lack of distinctiveness, while it might prevent registration in the first place, does not make a mark "disentitled to protection in a court" in the sense of Section 11(e). The seven-year shield therefore remained intact against this line of attack.

On the question of whether numerals can at all be registered as trademarks, the Court noted that the 8th edition of Kerly on Trade Marks (a leading British text on trademark law) had stated that numerals are prima facie not distinctive and can be registered only upon proof of extensive use. However, the 9th edition of the same work departed from this position and noted that numerals are capable of registration and that marks consisting of numerals do in fact exist. The Court also noted that Rules 139 and 140 of the Trade and Merchandise Marks Rules, 1959, permitted numerals to be registered as trademarks only in the case of textile goods, reflecting a long-standing practice in that particular trade. However, the Court held that it is not an inflexible rule that a numeral cannot be distinctive or registerable in other contexts, particularly if it has gained distinctiveness through extensive use. The Appellants' own counsel had conceded this point.

The most factually rich part of the analysis concerned Clause (c) of Section 32 — the question of whether the marks "50" and "Fifty" were distinctive of the Respondent's goods at the commencement of the proceedings. The Court noted that distinctiveness can be lost in several ways: if the goods can no longer be distinguished as those of the registered proprietor, if there is such extensive piracy that the marks have become public property, or if the proprietor has effectively abandoned the marks. The underlying principle is that a trademark has value only so long as it continues to connect the proprietor's goods in the minds of the public. Once that connection is broken, there is no justification for keeping the mark on the register.

The Court found on the facts that the marks had not lost their distinctiveness. The Respondent had been vigilant in enforcing its rights. When it found in 1954 that M/s. Indian Union Manufacturers Ltd. of Calcutta had begun inscribing the word "Fifty" on its bells, the Respondent promptly filed an infringement suit. That suit resulted in a compromise on February 5, 1955, under which the Indian Union company acknowledged the Respondent's exclusive rights to "Fifty," "Thirty," "50," and "30," while the Respondent in turn recognised the Indian Union company's right to "Thirty one," "Forty one," "Fifty one," "31," "41," and "51." Similarly, when the Respondent became aware of the mark "Five 50" being used by K.R. Berry & Co. of Jullundur, it gave notice and filed a suit, even though the suit had to be withdrawn later due to a jurisdictional defect in the Banaras court. Separately, the Respondent had filed opposition before the Registrar against an application by that company for registration of the mark "Five Fifty." The infringement suits against the two Appellant companies themselves were filed in 1959, as soon as the Respondent came to know of their use of the marks.

The Court also observed that the evidence of use of "50" by others in the market was neither extensive nor clearly established. The foreign cycle bells of Lucas and other companies with the numeral "50" inscribed on them had been used by those companies merely as type marks to distinguish one variety of bell from another, not as trademarks in the proper sense. Import of those bells had been prohibited around 1952, and whatever sales continued until 1958 were from old remaining stocks, which the Court characterised as "few and far between." There was no evidence at all of actual deception or confusion. Witnesses had testified that customers identified the Respondent's bells as "Asia bells" and in some cases as "Asia 50," suggesting that the numeral "50" had come to be associated with the Respondent's brand rather than functioning merely as a type descriptor.

The Court also addressed the Appellants' argument that the Respondent's failure to chase every infringer amounted to abandonment of the marks. Referring to the English case of Re. Farina (1879) 27 W.R. 456, the Court held that mere neglect to proceed against infringements does not necessarily constitute abandonment, particularly where those infringements are not of sufficient scale to affect the distinctiveness of the mark, even if the proprietor is aware of them. The Court further cited Rowland v. Mitchell (1897) 14 R.P.C. 37 for the proposition that in assessing whether a registered proprietor is barred by neglect to challenge infringements, one must consider the character and extent of the infringers' trade and their position in the market. The Appellants had not led evidence to show the extent of manufacture and sale of other bells with "50" inscribed on them, making it impossible to conclude that those infringements were of such a scale as to render the marks common property or to destroy their distinctive character.

Finally, the Court addressed the proper interpretation of the phrase "commencement of the proceedings" in Clause (c) of Section 32. It held that this phrase refers to the commencement of the proceedings in which the question of the conclusive character of the registration arises — which could be either the infringement suit or the rectification proceedings. In the present case, whether the crucial date was taken as 1959 (when the infringement suits were filed) or 1961 (when the rectification applications were filed), the result was the same: the marks had not ceased to be distinctive by either date.

Final Decision of the Court

The Supreme Court, by its judgment dated March 18, 1970, dismissed both civil appeals filed by National Bell Co. and Gupta Industrial Corporation. The appeals were dismissed with costs, with one hearing fee ordered. The Division Bench's judgment upholding both registered trademarks — the numeral "50" (Trade Mark No. 161543) and the word "Fifty" (Trade Mark No. 161544) — was confirmed. The Respondent's registrations were held to be valid and could not be cancelled on the grounds urged by the Appellant companies.

Points of Law Settled in the Case

This judgment settled a cluster of important principles of Indian trademark law that remain relevant to this day. The seven-year conclusiveness rule under Section 32 of the Trade and Merchandise Marks Act, 1958 — now broadly replicated in the Trade Marks Act, 1999 — creates a near-absolute shield after seven years from the date of original registration. Once seven years pass, the validity of registration cannot be challenged on the ground that the mark was not distinctive at the date of its registration or that distinctiveness was not proven before the Registrar. The only grounds of challenge that survive after seven years are fraud in obtaining registration, contravention of Section 11, and absence of distinctiveness at the date of commencement of the proceedings in question.

Critically, the judgment settled that Section 11(e) — which prohibits marks that would be "disentitled to protection in a court" — is not the same as Section 9. A mark that is merely not registerable because it lacks distinctiveness does not automatically become "disentitled to protection in a court." The word "disentitled" implies an active, substantive legal disqualification inherent in the mark itself, such as deceptiveness, illegality, or obscenity, not merely the absence of distinctiveness. This distinction is fundamental to understanding how the seven-year shield works in practice.

The judgment also affirmed that numerals are capable of being registered as trademarks and of acquiring distinctiveness through use, and that there is no absolute rule excluding them from trademark protection simply because they are numbers. The Court further established the principle that mere neglect to prosecute every infringer is not equivalent to abandonment of a trademark, provided the infringements are not of such a scale and nature as to render the mark common property in the market, and provided the proprietor takes action against significant infringers when it becomes aware of them.


Case Details

Title: National Bell Co. and Gupta Industrial Corporation Vs. Metal Goods Mfg. Co. (P) Ltd. and Anr. Date of Order: March 18, 1970 Case Number: Civil Appeal Nos. 1952 and 1953 of 1966 Neutral Citation: MANU/SC/0369/1970 Equivalent Citations: AIR 1971 SC 898; (1970) 3 SCC 665; [1971] 1 SCR 70 Court: Supreme Court of India Hon'ble Judges: Justice C.A. Vaidialingam and Justice J.M. Shelat


Disclaimer: Readers are advised not to treat this as a substitute for legal advice as it may contain errors in perception, interpretation, and presentation.

Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi


Suggested SEO Titles

  1. Can a Number Be a Trademark? Supreme Court's Landmark Ruling on Numerals and Distinctiveness in India
  2. The Seven-Year Trademark Shield: Supreme Court Explains Section 32 of Trade and Merchandise Marks Act in National Bell Case
  3. National Bell Co. vs Metal Goods: When "50" Became a Valid Trademark — Supreme Court of India 1970
  4. Trademark Distinctiveness of Numerals: Lessons from India's Supreme Court in the Cycle Bell Case
  5. Trademark Cancellation After Seven Years: What Can and Cannot Be Challenged Under Indian Law
  6. Disentitled vs Not Entitled: The Critical Trademark Distinction Settled by India's Supreme Court in 1970
  7. Abandonment of Trademarks and the Conclusiveness Rule: Supreme Court's Analysis in the National Bell Case

SEO Tags

National Bell Co vs Metal Goods Mfg Co, numeral trademark India, trademark distinctiveness numerals, Section 32 Trade and Merchandise Marks Act 1958, seven year conclusiveness trademark India, trademark cancellation rectification India, Section 11 Trade and Merchandise Marks Act, disentitled to protection trademark, trademark abandonment India, cycle bell trademark case India, Supreme Court trademark judgment 1970, AIR 1971 SC 898, MANU SC 0369 1970, trademark registration numerals India, Section 56 Trade and Merchandise Marks Act, Justice JM Shelat trademark, trademark piracy public juris, honest use trademark India, trademark distinctiveness loss, Kerly on Trade Marks numerals, Imperial Tobacco Co v De Pasquali, commencement of proceedings trademark, Part A register trademark India, trademark infringement cycle bells, AdvocateAjayAmitabhSuman, IPAdjutor


Headnote

National Bell Co. and Gupta Industrial Corporation v. Metal Goods Mfg. Co. (P) Ltd. and Anr., Civil Appeal Nos. 1952 and 1953 of 1966, decided March 18, 1970, Supreme Court of India (Justice C.A. Vaidialingam and Justice J.M. Shelat) — Trade and Merchandise Marks Act, 1958, Sections 2, 9, 9(3), 11, 28, 31, 32, 35, 46, 56, 56(2), 111; Trade and Merchandise Marks Rules, 1959, Rules 139 and 140; Trade Marks Act, 1905, Sections 11 and 41 — Rectification of Register — Numerals as Trademarks — Seven-Year Conclusiveness — Distinctiveness — The Respondent had obtained registered trademarks for the numeral "50" (No. 161543) and the word "Fifty" (No. 161544) in respect of cycle bells on November 20, 1953. The Appellants, manufacturers of cycle bells using the numeral "50" on their goods, filed rectification applications in 1961 seeking cancellation of the registrations on grounds of lack of distinctiveness, common use, and disentitlement to protection in court. Held: (i) After expiry of seven years from the date of registration, validity of a trade mark cannot be challenged on the ground that it was not distinctive at the date of registration or that distinctiveness was not proven before the Registrar; Section 32 creates a near-conclusive shield subject only to three exceptions. (ii) Section 11(e) — which prohibits marks "disentitled to protection in a court" — is distinct from Section 9 and refers only to marks having some inherent positive legal disqualification, such as deceptiveness or illegality; a mark that merely lacks distinctiveness is not thereby "disentitled to protection." (iii) Numerals are capable of being registered as trademarks and of acquiring distinctiveness by use; there is no absolute rule to the contrary. (iv) Distinctiveness of a registered mark under Section 32(c) must be assessed at the commencement of the relevant proceedings, not at the date of registration; a mark is not deprived of distinctiveness by sparse and unchallenged infringements, provided the proprietor takes reasonably prompt action against significant infringers. (v) Mere neglect to prosecute infringers does not constitute abandonment of a trademark unless the infringements are of such scale and character as to render the mark public property. (vi) The plea of common use requires proof of substantial use by others; isolated instances of use by competitors do not suffice. Appeals dismissed with costs.

Blog Archive

Featured Post

WHETHER THE REGISTRAR OF TRADEMARK IS REQUIRED TO BE SUMMONED IN A CIVIL SUIT TRIAL PROCEEDING

WHETHER THE REGISTRAR OF TRADEMARK IS REQUIRED TO BE SUMMONED IN A CIVIL SUIT TRIAL PROCEEDING IN ORDER TO PROVE THE TRADEMARK  REGISTRA...

My Blog List

IPR UPDATE BY ADVOCATE AJAY AMITABH SUMAN

IPR UPDATE BY ADVOCATE AJAY AMITABH SUMAN

Search This Blog